title: Repair effect of diabetic ulcers with recombinant human epidermal growth factor loaded by sustained-release microspheres.
abstract: In this study the w/o/w extraction-evaporation technique was adopted to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres loading recombinant human epidermal growth factor (rhEGF). The microspheres were characterized for morphology by transmission electron microscopy (TEM) and particle size distribution. The release performances, the proliferation effects and therapeutic effects of rhEGF-loaded PLGA microspheres were all studied. The results showed that these spherical microspheres had a narrow size distribution and a high drug encapsulation efficiency (85.6%). RhEGF-loaded microspheres enhanced the growth rate of fibroblasts and wound healing more efficiently than pure rhEGF. The number of the proliferating cell nuclear antigen (PCNA) in the epidermis layer with the microsphere treatment was significantly larger than those of the control groups. Overall locally sustained delivery of rhEGF from biodegradable PLGA microspheres may serve as a novel therapeutic strategy for diabetic ulcer repair.
authors.affiliation: Institute of Nanobiotechnology, School of Materials Science and Engineering, Tianjin University, Tianjin, 300072, China.
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Dong
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.forename: Weicai
authors.initials: W
authors.lastname: Wang
authors.forename: Hao
authors.initials: H
authors.lastname: Luo
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Liang
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Hanjie
authors.initials: H
authors.lastname: Wang
authors.forename: Penghua
authors.initials: P
authors.lastname: Wang
authors.forename: Jin
authors.initials: J
authors.lastname: Chang
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D003692:Delayed-Action Preparations; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000473:pathology; D017719:Diabetic Foot / Q000188:drug therapy* / Q000473:pathology; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D005347:Fibroblasts / Q000187:drug effects / Q000473:pathology; D019344:Lactic Acid; D008297:Male; D008863:Microspheres; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage
chemical_list: D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004815:Epidermal Growth Factor